Jasper Therapeutics, Inc. (JSPR) Stock Price, Financial Report, & Fundamental AnalysisNASDAQ:JSPR
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of conditioning agents and stem cell engineering to allow expanded use of stem cell transplantation and ex vivo gene therapy, a technique in which genetic manipulation of cells is performed outside the body prior to transplantation.
Jasper Therapeutics, Inc. Fundamental Analysis
Net Income Growth
JSPR has had growing net income for the last 2 years
Price to Book (PBV) Ratio
Undervalued price-to-book. JSPR stock price is under 1x the price-to-book value.
Debt-Equity Ratio (DER)
JSPR equity is higher than it's debt.
Small market capitalization. Market capitalization is less than 2bn USD
JSPR has never had growing revenue.
JSPR never has positive net income for 2 years.
JSPR has low dividend yield (0%).
Return of Assets
JSPR has low return of asset (-5.77%).
Return of Equity
JSPR has low return of equity (-5.59%).
JSPR never has positive revenue for 2 years.
Return of Invested Capital
JSPR has low ROIC.
Jasper Therapeutics, Inc. Financials
Financial statements are written records that convey the business activities and the financial performance of a company. Financial statements include the balance sheet, income statement, and statement of cash flow.
Also known as the profit and loss (P&L) statement or the statement of revenue and expense, the income statement primarily focuses on the company’s revenue and expenses during a particular period.
- 0 USD
- 36,833,000 USD
- Net Income
- -30,637,000 USD
- Profit Margin
A cash flow statement is a financial statement that provides aggregate data regarding all cash inflows a company receives from its ongoing operations and external investment sources. It also includes all cash outflows that pay for business activities and investments during a given period.
- Free Cash Flow
- -36,106,000 USD
Liquidity & Solvency
Solvency refers to an company's capacity to meet its long-term financial commitments. Liquidity refers to an company's ability to pay short-term obligations. The term also refers to a company's capability to sell assets quickly to raise cash.
Short Term Liabilities
Long Term Liabilities
|Dividend Payout Ratio (DPR)||0%|
|Dividend Payout Ratio (DPR)||0%|
|Dividend per Share||0,00 USD|
|Price to Earning (PER)||0.1x|
|Price to Earning-Growth (PEG)||0x|
|Price to Book Value (PBV)||0x|
|Debt-Equity Ratio (DER)||24.27%|
|Net Profit Margin (NPM)||0%|
|Return of Assets (ROA)||-5.77%|
|Return of Equity (ROE)||-5.59%|
|Return on Capital Employed (ROCE)||-91.95%|
|Days of Sales Outstanding (DSO)||0|
|Days of Inventory Outstanding (DIO)||0|
|Days Payable Outstanding (DPO)||0|
|Operating Cycle (OC)||0|
|Cash Conversion Cycle (CCC)||0|
Jasper Therapeutics, Inc. Executives
- CEO Name
Jasper Therapeutics, Inc. Profile
About Jasper Therapeutics, Inc.
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of conditioning agents and stem cell engineering to allow expanded use of stem cell transplantation and ex vivo gene therapy, a technique in which genetic manipulation of cells is performed outside the body prior to transplantation. The company's lead product candidate is JSP191, which is in clinical development as a conditioning antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It is also developing engineered hematopoietic stem cells product candidates to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. The company is based in Redwood City, California.
- Company name
- Jasper Therapeutics, Inc.
- NASDAQ Capital Market
2200 Bridge Parkway